IceCure Medical Ltd (NASDAQ:ICCM – Get Rating) – Equities research analysts at HC Wainwright cut their Q3 2023 earnings per share (EPS) estimates for IceCure Medical in a report released on Tuesday, May 23rd. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings of ($0.09) per share for the quarter, down from their prior forecast of ($0.08). HC Wainwright has a “Buy” rating and a $3.00 price objective on the stock. The consensus estimate for IceCure Medical’s current full-year earnings is ($0.36) per share. HC Wainwright also issued estimates for IceCure Medical’s Q4 2023 earnings at ($0.09) EPS, FY2023 earnings at ($0.35) EPS and FY2024 earnings at ($0.30) EPS.
IceCure Medical (NASDAQ:ICCM – Get Rating) last posted its earnings results on Monday, May 22nd. The company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.09) by $0.01. IceCure Medical had a negative return on equity of 79.90% and a negative net margin of 534.74%. The company had revenue of $0.71 million for the quarter, compared to the consensus estimate of $0.95 million. During the same quarter in the prior year, the business earned ($0.12) earnings per share.
IceCure Medical Price Performance
Hedge Funds Weigh In On IceCure Medical
Several institutional investors and hedge funds have recently made changes to their positions in the company. JPMorgan Chase & Co. acquired a new stake in IceCure Medical during the second quarter worth approximately $78,000. Boothbay Fund Management LLC lifted its stake in IceCure Medical by 100.0% during the fourth quarter. Boothbay Fund Management LLC now owns 40,000 shares of the company’s stock worth $62,000 after purchasing an additional 20,000 shares during the last quarter. Bank of America Corp DE lifted its stake in IceCure Medical by 57.2% during the fourth quarter. Bank of America Corp DE now owns 55,388 shares of the company’s stock worth $86,000 after purchasing an additional 20,159 shares during the last quarter. Finally, UBS Group AG lifted its stake in IceCure Medical by 1,302.3% during the fourth quarter. UBS Group AG now owns 28,986 shares of the company’s stock worth $45,000 after purchasing an additional 26,919 shares during the last quarter.
About IceCure Medical
IceCure Medical Ltd, a medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a cryoablation solution for the treatment of breast tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.
- Get a free copy of the StockNews.com research report on IceCure Medical (ICCM)
- Ralph Lauren’s Styled Dividend Is Still In Season
- Dollar Tree Falls As Theft Cuts Into Bottom Line
- Best Buy’s Comeback Is Still At Play, Earnings Call For Patience
- e.l.f. Beauty Has Giant Quarter, Shares Hit New High
- If You Can Only Pick One Stock For The Rest Of 2023, Pick Nvidia
Receive News & Ratings for IceCure Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IceCure Medical and related companies with MarketBeat.com's FREE daily email newsletter.